Compare care options for Obsessive-Compulsive Disorder

See what we know about each option. We may not have all options. This page does not pick one for you.

Pick up to 4 care options

You can share this page. You do not need an account.

3 selected

What we found

Each option is for Obsessive-Compulsive Disorder. Research and local care are different facts.

Sertraline

What it is

We have not added a short description yet.

Why it is on this page

People: patients with obsessive-compulsive disorder as labeled

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: labeled indication

Statement scope

Formulation or format: tablet, film coated; oral solution
Indication: obsessive-compulsive disorder
Population: patients with obsessive-compulsive disorder as labeled
Section code: 34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Source: DailyMed sertraline (Zoloft) label. Checked Oct 16, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/fda754f6-d0f3-4dce-a17a-927d64f912f7.xml

Research for Obsessive-Compulsive Disorder

Not reviewed

No current published assessment exists for this exact Treatment and Need. This does not establish benefit or no benefit.

Compared with the others: Not directly compared. We show each option’s own research.

See the research Find care

CLOMIPRAMINE HYDROCHLORIDE

What it is

We have not added a short description yet.

Why it is on this page

People: patients with Obsessive-Compulsive Disorder whose obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning (DSM-III-R); labeled effectiveness data include adults and children and adolescents 10 to 17 years of age

DailyMed clomipramine (Anafranil) label · checked Oct 16, 2026

Relationship: labeled indication

Statement scope

Formulation or format: capsule
Indication: treatment of obsessions and compulsions in Obsessive-Compulsive Disorder (OCD)
Labeler: SpecGx LLC
Population: patients with Obsessive-Compulsive Disorder whose obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning (DSM-III-R); labeled effectiveness data include adults and children and adolescents 10 to 17 years of age
Product: ANAFRANIL (clomipramine hydrochloride) capsule
Section code: 34067-9

Source collection coverage: country:US

Pointer: /sections/0

Supporting passage: Anafranil ™ (clomipramine hydrochloride) Capsules USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).

Open source

Source: DailyMed clomipramine (Anafranil) label. Checked Oct 16, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/4074b555-7635-41a9-809d-fae3b3610059.xml

Research for Obsessive-Compulsive Disorder

Not reviewed

No current published assessment exists for this exact Treatment and Need. This does not establish benefit or no benefit.

Compared with the others: Not directly compared. We show each option’s own research.

See the research Find care

Fluoxetine

What it is

We have not added a short description yet.

Why it is on this page

People: adults and pediatric patients 7 to 17 years of age with Obsessive Compulsive Disorder (OCD), as labeled

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: labeled indication

Statement scope

Formulation or format: tablets (product labeled Fluoxetine Hydrochloride capsule; Indications and Usage text refers to Fluoxetine Tablets; 60-mg scored tablet dosage form)
Indication: Obsessive Compulsive Disorder (OCD)
Population: adults and pediatric patients 7 to 17 years of age with Obsessive Compulsive Disorder (OCD), as labeled
Section code: 34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Oct 16, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Research for Obsessive-Compulsive Disorder

Not reviewed

No current published assessment exists for this exact Treatment and Need. This does not establish benefit or no benefit.

Compared with the others: Not directly compared. We show each option’s own research.

See the research Find care

Page link: https://everyoption.org/compare/ocd?treatments=sertraline%2Cclomipramine%2Cfluoxetine&locale=en-US